Ramucirumab and durvalumab for previously treated, advanced non–small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ)

Yung‐Jue Bang, Talia Golan, Laëtitia Dahan, Siqing Fu, Víctor Moreno, Keunchil Park, Ravit Geva, Filippo de Braud, Zev A. Wainberg, Martin Reck, Laura W. Goff, Naomi Laing, Gu Mi, Joana Oliveira, Heather Wasserstrom, Chia‐Chi Lin